Dec 24 (Reuters) - Sanofi (SASY.PA) said on Wednesday it will buy U.S. biotech Dynavax Technologies (DVAX.O) for around $2.2 ...

Following a feud with activist investor Deep Track Capital in the first half of 2025, vaccine developer Dynavax Technologies ...

The world's largest bio investment event, the JP Morgan Healthcare Conference (JPMHC), is just a week away. With the total ...

GSC Grays has appointed Katherine Wigham, a specialist with nearly two decades of experience in the leisure property sector, to head up its newly launched Rural Business & Leisure Agency.

"People have to take a step back and understand what it is and how it can be a big help to developers and be a tremendous ...

GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory RNA-targeting therapeutics in neurodegenerative and kidney disease indications.

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

We recently published 13 Best ADR Stocks to Invest In. GSK plc (NYSE:GSK) is one of the best ADR stocks. GSK plc (NYSE:GSK) is one of the largest pharmaceutical companies in the world. The firm scored ...

Adopt AI, accelerate development and increase velocity. With 84% of respondents to the Stack Overflow 2025 Developer Survey ...

With an increase in the antimicrobial resistance to therapies for gonorrhea, doctors have been left with fewer options to treat the sexually transmitted infection (STI), which strikes more an 80 ...

Rival European pharma giants Sanofi and GSK have both forged new partnerships to bolster their preclinical research. Paris-based Sanofi is investing in a U.S. biotech’s autoimmune research, while GSK ...

CAMP4 Therapeutics Corporation ( ($CAMP) ) has provided an announcement. On December 17, 2025, CAMP4 Therapeutics entered into a strategic ...